

SEP 10 2004

510(k) Summary

Prepared on July 1, 2004

This 510(k) Summary is submitted in accordance with 21 CFR 807.92.

Trade Name: 5.2F Dual-Lumen Extended Length Catheter (dELC)

Manufacturer: CHF Solutions, Inc., Suite 170 – 7601 Northland Drive, Brooklyn Park, MN 55428

Official Contact: Amy Peterson
Vice President, RA & QA
Telephone: 763-463-4620
Fax: 763-463-4606

Generic Name: Short-term/non-implanted blood access device

Classification:

<u>Aquadex™ System 100 - Accessory</u>	<u>Non-implanted Blood Access Device</u>
• Class: II (21 CFR 876.5860)	• Class: II (21 CFR 876.5540 (b)(2))
• Panel: Gastroenterology-Urology	• Panel: Gastroenterology-Urology
• Product code: KDI	• Product code: MPB

Predicate Devices:

- CHF Solutions, 6F dELC (K031869)
- CHF Solutions, Extended Length Catheter (K013733)

Device Description: The 5.2F dELC is a 16 gauge, polyurethane, dual lumen extended-length catheter. It is intended to provide short-term peripheral venous access to facilitate blood removal and return for the purposes of ultrafiltration. The catheter has a low profile, flexible hub with suture wings for securement to the skin. The dual lumen tubing in the proximal portion of the catheter shaft is a double-D configuration and is fused to a single lumen tube for the distal portion. The catheter shaft construction includes a 304 stainless steel coil to minimize kinking from bending. The blood is drawn up through the single lumen tubing, and infused back into the vessel through the short proximal dual lumen section of the catheter shaft. The catheter will connect directly to the UF circuit of the Aquadex System 100 to conduct blood to and from the patient for the purposes of ultrafiltration. The 5.2F dELC is compatible with the Aquadex System 100 which utilizes software allowing blood flow rate adjustment as this catheters' optimal blood flow rate is at ≤ 20 ml/minute.

Indication for Use: The 5.2F dELC catheter is a peripheral venous access catheter, inserted preferably in the basilic vein (arm) and antecubital region respectively and specifically for use with the Aquadex™ System 100 when the blood flow rate is set at ≤ 20 ml/minute.

The catheter not intended for the infusion of medications or fluids, for laboratory sampling, or other venous access needs.

The Aquadex System 100 is indicated for temporary (up to 8 hours) ultrafiltration treatment of patients with fluid overload.

Safety & Performance: The 5.2F dELC and predicate devices are similar in materials of construction and identical for packaging and sterilization. The dELC is provided sterile and nonpyrogenic. Bench tests demonstrate the dELC is compatible with the Aquadex System 100 which utilizes software allowing blood flow rate adjustment to ≤ 20 ml/minute.

Conclusion: Based on the intended use, technology characteristics and bench testing, the new access catheter has been shown to be safe and effective for its intended use. This product is substantially equivalent¹⁰ and considered acceptable for the intended use.

¹⁰ This document uses the term "substantial equivalent" as intended in 21 CFR 807.87 and not as defined in Title 36 of the U.S. Code.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

SEP 10 2004

Mr. Steve Bernard
Director, Disposable Development
CHF Solutions, Inc.
Suite 170
7601 Northland Drive
BROOKLYN PARK MN 55428

Re: K041791

Trade/Device Name: Aquadex™ System 100 – 5.2F/16G Dual Lumen Extended Length
Catheter (dELC), Model A1562

Regulation Number: 21 CFR §876.5540

Regulation Name: Blood access device and accessories

Regulatory Class: II

Product Code: 78 NQJ

Dated: July 1, 2004

Received: July 6, 2004

Dear Mr. Bernard:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of the letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT
(Page 1 of 1)

510(k) Number (if know): K04 1791

Device Name: 5.2F Dual Lumen Extended Length Catheter (dELC)

Indication For Use for device:


The 5.2F dELC catheter is a peripheral venous access catheter, inserted preferably in the basilic vein (arm) and antecubital region respectively and specifically for use with the Aquadex™ System 100 when the blood flow rate is set at ≤ 20 ml/minute.

The catheter is not intended for the infusion of medications or fluids, for laboratory sampling, or other venous access needs.

The Aquadex System 100 is indicated for temporary (up to 8 hours) ultrafiltration treatment of patients with fluid overload.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices

510(k) Number K041791

Prescription Use
(Per 21 CFR 801.109)

OR

Over-The-Counter Use